[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Geron Corp (GERN)

Geron Corp (GERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 961,350
  • Shares Outstanding, K 640,900
  • Annual Sales, $ 183,880 K
  • Annual Income, $ -83,500 K
  • EBIT $ -52 M
  • EBITDA $ -56 M
  • 60-Month Beta 0.67
  • Price/Sales 5.40
  • Price/Cash Flow N/A
  • Price/Book 4.38

Options Overview Details

View History
  • Implied Volatility 84.98% (-9.67%)
  • Historical Volatility 68.93%
  • IV Percentile 8%
  • IV Rank 5.42%
  • IV High 429.98% on 10/10/25
  • IV Low 65.22% on 06/04/25
  • Expected Move (DTE 21) 0.2125 (14.17%)
  • Put/Call Vol Ratio 0.16
  • Today's Volume 253
  • Volume Avg (30-Day) 624
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 49,752
  • Open Int (30-Day) 53,023
  • Expected Range 1.2875 to 1.7125

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.03
  • Number of Estimates 4
  • High Estimate $-0.02
  • Low Estimate $-0.03
  • Prior Year $-0.03
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3800 +8.70%
on 03/30/26
1.8399 -18.47%
on 04/07/26
-0.0100 (-0.66%)
since 03/24/26
3-Month
1.2900 +16.28%
on 01/29/26
2.0100 -25.37%
on 02/19/26
+0.1200 (+8.70%)
since 01/23/26
52-Week
1.0400 +44.23%
on 11/07/25
2.0100 -25.37%
on 02/19/26
+0.0800 (+5.63%)
since 04/24/25

Most Recent Stories

More News
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026

FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.5000 (unch)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock...

GERN : 1.5000 (unch)
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a...

GERN : 1.5000 (unch)
Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary

FOSTER CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.5000 (unch)
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference

FOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.5000 (unch)
Geron Announces Appointment of New Members to its Board of Directors

FOSTER CITY, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.5000 (unch)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective March 17, 2026, it granted stock...

GERN : 1.5000 (unch)
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END

AVAI : 0.3100 (+1.64%)
NAGE : 4.93 (+4.23%)
GERN : 1.5000 (unch)
NTLA : 13.63 (-14.11%)
OCGN : 1.6600 (-0.60%)
Geron: Q4 Earnings Snapshot

Geron: Q4 Earnings Snapshot

GERN : 1.5000 (unch)
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Achieved $48 million and $184 million in RYTELO ® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025,...

GERN : 1.5000 (unch)

Business Summary

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic...

See More

Key Turning Points

3rd Resistance Point 1.5800
2nd Resistance Point 1.5600
1st Resistance Point 1.5300
Last Price 1.5000
1st Support Level 1.4800
2nd Support Level 1.4600
3rd Support Level 1.4300

See More

52-Week High 2.0100
Fibonacci 61.8% 1.6395
Fibonacci 50% 1.5250
Last Price 1.5000
Fibonacci 38.2% 1.4105
52-Week Low 1.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.